Cellectis Bioresearch, Syngene Partner on Cell Line Development | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cellectis bioresearch and Indian contract research organization Syngene International said today they will co-develop novel genetically customized cell lines.

The collaboration between the two companies will leverage Paris-based Cellectis bioresearch's genome customization technology and Syngene's biology platform and capabilities to develop recombinant and knock-out cell lines for oncology and ADME-Tox-based drug discovery research.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.